Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.64 |
| ▸ | RAF1 | P04049 | 15/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692928 | 0.93 | BRAF (0.56) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL13680228 | 0.90 | BRAF (0.62) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL19916608 | 0.88 | RAF1 (0.60) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL19258530 | 0.88 | RAF1 (0.60) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL13680209 | 0.86 | RET (0.52) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL19258524 | 0.86 | BRAF (0.64) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL16692921 | 0.86 | BRAF (0.54) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL16692920 | 0.85 | BRAF (0.71) | BRAFRAF1 | |
| SCHEMBL19258533 | 0.84 | BRAF (0.66) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL13680218 | 0.83 | BRAF (0.64) | BRAFRAF1RETKIF5BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |